Acute Myeloid Leukemia

Section 4 - Acute Myeloid Leukemia

Published online by Cambridge University Press: 20 May 2026

Edited by

Wei Wang and

Sa A. Wang

Show author details

Wei Wang: Affiliation:
The University of Texas MD Anderson Cancer Center
Sa A. Wang: Affiliation:
The University of Texas MD Anderson Cancer Center

Book contents

Get access

Summary

This chapter introduces the classification of acute myeloid leukemia (AML) and highlights integrating both genetic and immunophenotypic findings in the diagnostic process. AML blasts exhibit a diverse immunophenotypic profile, and key markers associated with each immunophenotypic subtype are discussed. The assessment of measurable residual disease (MRD) is crucial in AML, as it provides important information regarding treatment response and prognosis. Both flow cytometry and molecular testing are used in MRD evaluation.

Information

Type: Chapter
Information: Flow Cytometry in Hematolymphoid Neoplasms
A Comprehensive and Practical Guide to Diagnosis
, pp. 223 - 316
DOI: https://doi.org/10.1017/9781009397797 [Opens in a new window]
Publisher: Cambridge University Press
Print publication year: 2026

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

Mason, EF, Hasserjian, RP, Aggarwal, N, Seegmiller, AC, Pozdnyakova, O. Blast phenotype and commutations in acute myeloid leukemia with mutated NPM1 influence disease biology and outcome. Blood Adv 2019; 3(21): 3322–3332.10.1182/bloodadvances.2019000328CrossRef Google Scholar

Kuusanmaki, H, Dufva, O, Vaha-Koskela, M, Leppa, AM, Huuhtanen, J, Vanttinen, I, et al. Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia. Blood 2023; 141(13): 1610–1625.10.1182/blood.2021011094CrossRef Google Scholar PubMed

Pei, S, Pollyea, DA, Gustafson, A, Stevens, BM, Minhajuddin, M, Fu, R, et al. Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia. Cancer Discov 2020; 10(4): 536–551.10.1158/2159-8290.CD-19-0710CrossRef Google Scholar PubMed

Mason, KD, Juneja, SK, Szer, J. The immunophenotype of acute myeloid leukemia: Is there a relationship with prognosis? Blood Rev 2006; 20(2): 71–82.10.1016/j.blre.2005.08.002CrossRef Google Scholar

Heuser, M, Freeman, SD, Ossenkoppele, GJ, Buccisano, F, Hourigan, CS, Ngai, LL, et al. 2021 update on MRD in acute myeloid leukemia: A consensus document from the European LeukemiaNet MRD Working Party. Blood 2021; 138(26): 2753–2767.10.1182/blood.2021013626CrossRef Google Scholar PubMed

Jen, WY, Sasaki, K, Ravandi, F, Kadia, TM, Wang, SA, Wang, W, et al. Impact of measurable residual disease clearance kinetics in patients with AML undergoing intensive chemotherapy. Blood Adv 2024; 9(4): 783–792.10.1182/bloodadvances.2024013826CrossRef Google Scholar

References

Faber, ZJ, Chen, X, Gedman, AL, Boggs K, Cheng J, Ma J, et al. The genomic landscape of core-binding factor acute myeloid leukemias. Nat Genet 2016; 48(12): 1551–1556.10.1038/ng.3709CrossRef Google Scholar PubMed

Shang, L, Chen, X, Liu, Y, Cai, X, Shi, Y, Shi, L, et al. The immunophenotypic characteristics and flow cytometric scoring system of acute myeloid leukemia with t(8;21) (q22;q22); RUNX1-RUNX1T1. Int J Lab Hematol 2019; 41(1): 23–31.10.1111/ijlh.12916CrossRef Google Scholar

Yang, DH, Lee, JJ, Mun, YC, Shin, HJ, Kim, YK, Cho, SH, et al. Predictable prognostic factor of CD56 expression in patients with acute myeloid leukemia with t(8:21) after high dose cytarabine or allogeneic hematopoietic stem cell transplantation. Am J Hematol 2007; 82(1): 1–5.10.1002/ajh.20739CrossRef Google Scholar PubMed

Ray, D, Kwon, SY, Tagoh, H, Heidenreich, O, Ptasinska, A, Bonifer, C. Lineage-inappropriate PAX5 expression in t(8;21) acute myeloid leukemia requires signaling-mediated abrogation of polycomb repression. Blood 2013; 122(5): 759–769.10.1182/blood-2013-02-482497CrossRef Google Scholar

Liu, H, Wang, SA, Schlette, EJ, Xu J, Jorgensen JL, Yin C, et al. Myeloid neoplasms with t(16;21)(q24;q22)/RUNX1-RUNX1T3 mimics acute myeloid leukemia with RUNX1-RUNX1T1. Ann Hematol 2018; 97(10): 1775–1783.10.1007/s00277-018-3389-3CrossRef Google Scholar

References

Wang, L, Wang, W, Beird, HC, Cheng, X, Fang, H, Tang, G, et al. PPP1R7 is a novel translocation partner of CBFB via t(2;16)(q37;q22) in acute myeloid leukemia. Genes (Basel) 2022; 13(8): 1367.Google Scholar

Schwind, S, Edwards, CG, Nicolet, D, Mrozek, K, Maharry, K, Wu, YZ, et al. inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB–MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations. Blood 2013; 121(2): 385–391.10.1182/blood-2012-07-442772CrossRef Google Scholar

Sameeta, F, Wang, SA, Tang, Z, Khoury, JD, Fang, H, Wang, D, et al. Integrative immunophenotypic and genetic characterization of acute myeloid leukemia with CBFB rearrangement. Am J Clin Pathol 2024; 162(5): 455–463.10.1093/ajcp/aqae060CrossRef Google Scholar PubMed

Schnittger, S, Bacher, U, Haferlach, C, Kern, W, Haferlach, T. Rare CBFB–MYH11 fusion transcripts in AML with inv(16)/t(16;16) are associated with therapy-related AML M4eo, atypical cytomorphology, atypical immunophenotype, atypical additional chromosomal rearrangements and low white blood cell count: A study on 162 patients. Leukemia 2007; 21(4): 725–731.10.1038/sj.leu.2404531CrossRef Google Scholar

Borthakur, G, Kantarjian, H. Core binding factor acute myelogenous leukemia-2021 treatment algorithm. Blood Cancer J 2021; 11(6): 114.10.1038/s41408-021-00503-6CrossRef Google Scholar PubMed

References

Fang, H, Wang, SA, Hu, S, Konoplev, SN, Mo, H, Liu, W, et al. Acute promyelocytic leukemia: Immunophenotype and differential diagnosis by flow cytometry. Cytometry B Clin Cytom 2022; 102(4): 283–291.10.1002/cyto.b.22085CrossRef Google Scholar PubMed

Gorczyca, W. Acute promyelocytic leukemia: Four distinct patterns by flow cytometry immunophenotyping. Pol J Pathol 2012; 63(1): 8–17.Google Scholar PubMed

Liu, M, Weng, X, Gong, S, Chen, H, Ding, J, Guo, M, et al. Flow cytometric analysis of CD64 expression pattern and density in the diagnosis of acute promyelocytic leukemia: A multi-center study in Shanghai, China. Oncotarget 2017; 8(46): 80625–80637.10.18632/oncotarget.20814CrossRef Google Scholar PubMed

Ren, F, Zhang, N, Xu, Z, Xu, J, Zhang, Y, Chen, X, et al. The CD9(+) CD11b(−) HLA-DR(−) immunophenotype can be used to diagnose acute promyelocytic leukemia. Int J Lab Hematol 2019; 41(2): 168–175.10.1111/ijlh.12929CrossRef Google Scholar PubMed

Touzet, L, Dumezy, F, Roumier, C, Berthon, C, Bories, C, Quesnel, B, et al. CD9 in acute myeloid leukemia: Prognostic role and usefulness to target leukemic stem cells. Cancer Med 2019; 8(3): 1279–1288.10.1002/cam4.2007CrossRef Google Scholar PubMed

Zhu, HH, Qin, YZ, Zhang, ZL, Liu, YJ, Wen, LJ, You, MJ, et al. A global study for acute myeloid leukemia with RARG rearrangement. Blood Adv 2023; 7(13): 2972–2982.10.1182/bloodadvances.2022008364CrossRef Google Scholar

Osumi, T, Tsujimoto, SI, Tamura, M, Uchiyama, M, Nakabayashi, K, Okamura, K, et al. Recurrent RARB translocations in acute promyelocytic leukemia lacking RARA translocation. Cancer Res 2018; 78(16): 4452–4458.10.1158/0008-5472.CAN-18-0840CrossRef Google Scholar PubMed

Ferrari, A, Bussaglia, E, Ubeda, J, Facchini, L, Aventin, A, Sierra, J, et al. Immunophenotype distinction between acute promyelocytic leukaemia and CD15− CD34− HLA-DR− acute myeloid leukaemia with nucleophosmin mutations. Hematol Oncol 2012; 30(3): 109–114.10.1002/hon.1011CrossRef Google Scholar PubMed

References

Falini, B, Bolli, N, Shan, J, Martelli, MP, Liso, A, Pucciarini, A, et al. Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. Blood 2006; 107(11): 4514–4523.10.1182/blood-2005-11-4745CrossRef Google Scholar PubMed

Falini, B, Brunetti, L. Sportoletti, P, Martelli, MP. NPM1-mutated acute myeloid leukemia: From bench to bedside. Blood 2020; 136(15): 1707–1721.10.1182/blood.2019004226CrossRef Google Scholar PubMed

Loghavi, S, DiNardo, CD, Furudate, K, Takahashi, K, Tanaka, T, Short, NJ, et al. Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemia. Br J Haematol 2021; 192(6): 1054–1063.10.1111/bjh.17347CrossRef Google Scholar PubMed

Mason, EF, Hasserjian, RP, Aggarwal, N, Seemiller, AC, Pozdnyakova, O. Blast phenotype and comutations in acute myeloid leukemia with mutated NPM1 influence disease biology and outcome. Blood Adv 2019; 3(21): 3322–3332.10.1182/bloodadvances.2019000328CrossRef Google Scholar PubMed

Ohan, H, Gomez-Gelvez, J, Shen, Y, Ghosh, S, Carey, J, Inamdar, K, et al. An unusual case of pure erythroid leukemia with normal karyotype and NPM1 mutation. J Hematop 2024; 17(3): 163–166.10.1007/s12308-024-00588-5CrossRef Google Scholar PubMed

Arber, DA, Chang, KL, Lyda, MH, Bedell, V, Spielberger, R, Slovak, ML. Detection of NPM/MLF1 fusion in t(3;5)-positive acute myeloid leukemia and myelodysplasia. Hum Pathol 2003; 34(8): 809–813.10.1016/S0046-8177(03)00251-XCrossRef Google Scholar

Dumezy, F, Renneville, A, Mayeur-Rousse, C, Nibourel, O, Labis, E, Preudhomme, C, et al. Acute myeloid leukemia with translocation t(3;5): New molecular insights. Haematologica 2013; 98(4): e52–e54.10.3324/haematol.2012.082149CrossRef Google Scholar PubMed

Falini, B, Bigerna, B, Pucciarini, A, Tiacci, E, Mecucci, C, Morris, SW, et al. Aberrant subcellular expression of nucleophosmin and NPM-MLF1 fusion protein in acute myeloid leukaemia carrying t(3;5): A comparison with NPMc+ AML. Leukemia 2006; 20(2): 368–371.10.1038/sj.leu.2404068CrossRef Google Scholar PubMed

Lim, G, Choi, JR, Kim, MJ, Kim, SY, Lee, HJ, Suh, JT, et al. Detection of t(3;5) and NPM1/MLF1 rearrangement in an elderly patient with acute myeloid leukemia: Clinical and laboratory study with review of the literature. Cancer Genet Cytogenet 2010; 199(2): 101–109.10.1016/j.cancergencyto.2010.02.009CrossRef Google Scholar

Martelli, MP, Rossi, R, Venanzi, A, Meggendorfer, M, Perriello, VM, Martino, G, et al. Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML. Blood 2021; 138(25): 2696–2701.10.1182/blood.2021012732CrossRef Google Scholar PubMed

Raimondi, SC, Dube, ID, Valentine, MB, Mirro, J Jr., Watt, HJ, Larson, RA, et al. Clinicopathologic manifestations and breakpoints of the t(3;5) in patients with acute nonlymphocytic leukemia. Leukemia 1989; 3(1): 42–47.Google Scholar

Zhou, Y, Jorgensen, JL, Wang, SA, Ravandi, F, Cortes, J, Kantarjian, HM, et al. Usefulness of CD11a and CD18 in flow cytometric immunophenotypic analysis for diagnosis of acute promyelocytic leukemia. Am J Clin Pathol 2012; 138(5): 744–750.10.1309/AJCPQU9R3FSLKFMICrossRef Google Scholar PubMed

Sameeta, F, Wang, W, Jelloul, FZ, Nwogbo, OV, Thakral, B, Xu, J, et al. The significance of detecting an unusual myeloblast immunophenotype in a presumptive clinical diagnosis of myelodysplastic syndromes. Arch Pathol Lab Med 2024; 149(8): 717–726.10.5858/arpa.2024-0228-OACrossRef Google Scholar

References

Dohner, H, Wei, AH, Appelbaum, FR, Craddock, C, DiNardo, CD, Dombret, H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 2022; 140(12): 1345–1377.10.1182/blood.2022016867CrossRef Google Scholar

Bill, M, Mrozek, K, Kohlschmidt, J, Eisfeld, AK, Walker, CJ, Nicolet, D, et al. Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/KMT2A. Proc Natl Acad Sci USA 2020; 117(42): 26340–26346.10.1073/pnas.2014732117CrossRef Google Scholar PubMed

Issa, GC, Zarka, J, Sasaki, K, Qiao, W, Pak, D, Ning, J, et al. Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements. Blood Cancer J 2021; 11(9): 162.10.1038/s41408-021-00557-6CrossRef Google Scholar PubMed

Konoplev, S, Wang, X, Tang, G, Li, S, Wang, W, Xu, J, et al. Comprehensive immunophenotypic study of acute myeloid leukemia with KMT2A (MLL) rearrangement in adults: A single-institution experience. Cytometry B Clin Cytom 2022; 102(2): 123–133.10.1002/cyto.b.22051CrossRef Google Scholar PubMed

Li, J and Kalev-Zylinska, ML. Advances in molecular characterization of pediatric acute megakaryoblastic leukemia not associated with Down syndrome: Impact on therapy development. Front Cell Dev Biol 2023; 11: 1170622.10.3389/fcell.2023.1170622CrossRef Google Scholar

Zhou, T, Curry, CV, Khanlari, M, Shi, M, Cui, W, Peker, D, et al. Genetics and pathologic landscape of lineage switch of acute leukemia during therapy. Blood Cancer J 2024; 14(1): 19.10.1038/s41408-024-00983-2CrossRef Google Scholar PubMed

References

Summerer, I, Haferlach, C, Meggendorfer, M, Kern, W, Haferlach, T, Stengel, A. Prognosis of MECOM (EVI1)-rearranged MDS and AML patients rather depends on accompanying molecular mutations than on blast count. Leuk Lymphoma 2020; 61(7): 1756–1759.10.1080/10428194.2020.1737689CrossRef Google Scholar PubMed

Rogers, HJ, Vardiman, JW, Anastasi, J, Raca, G, Savage, NM, Cherry, AM, et al. Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): A Bone Marrow Pathology Group study. Haematologica 2014; 99(5): 821–829.10.3324/haematol.2013.096420CrossRef Google Scholar

Groschel, S, Sanders, MA, Hoogenboezem, R, Zeilemaker, A, Havermans, M, Erpelinck, C, et al. Mutational spectrum of myeloid malignancies with inv(3)/t(3;3) reveals a predominant involvement of RAS/RTK signaling pathways. Blood 2015; 125(1): 133–139.10.1182/blood-2014-07-591461CrossRef Google Scholar

Lugthart, S, Groschel, S, Beverloo, HB, Kayser, S, Valk, PJ, Van Zelderen-Bhola, SL, et al. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. J Clin Oncol 2010; 28(24): 3890–3898.10.1200/JCO.2010.29.2771CrossRef Google Scholar

Medeiros, BC, Kohrt, HE, Arber, DA, Bangs, CD, Cherry, AM, Majeti, R, et al. Immunophenotypic features of acute myeloid leukemia with inv(3)(q21q26.2)/t(3;3)(q21;q26.2). Leuk Res 2010; 34(5): 594–597.10.1016/j.leukres.2009.08.029CrossRef Google Scholar

Raya, JM, Martin-Santos, T, Luno, E, Sanzo, C, Perez-Sirvent, ML, Such, E, et al. Acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2): Clinical and biological features and comparison with other acute myeloid leukemias with cytogenetic aberrations involving long arm of chromosome 3. Hematology 2015; 20(8): 435–441.10.1179/1607845415Y.0000000003CrossRef Google Scholar

References

Saito, S, Cigdem, S, Okuwaki, M, Nagata, K. Leukemia-associated Nup214 fusion proteins disturb the XPO1-mediated nuclear-cytoplasmic transport pathway and thereby the NF-kappaB signaling pathway. Mol Cell Biol 2016; 36(13): 1820–1835.10.1128/MCB.00158-16CrossRef Google Scholar PubMed

Potluri, S, Kellaway, SG, Coleman, DJL, Keane, P, Imperato, MR, Assi, SA, et al. Gene regulation in t(6;9) DEK::NUP214 acute myeloid leukemia resembles that of FLT3-ITD/NPM1 acute myeloid leukemia but with an altered HOX/MEIS axis. Leukemia 2024; 38(2): 403–407.10.1038/s41375-023-02118-1CrossRef Google Scholar

Fang, H, Yabe, M, Zhang, X, Kim, Y, Wu, X, Wei, P, et al. Myelodysplastic syndrome with t(6;9)(p22;q34.1)/DEK-NUP214 better classified as acute myeloid leukemia? A multicenter study of 107 cases. Mod Pathol 2021; 34(6): 1143–1152.10.1038/s41379-021-00741-wCrossRef Google Scholar

Slovak, ML, Gundacker, H, Bloomfield, CD, Dewald, G, Appelbaum, FR, Larson, RA, et al. A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare “poor prognosis” myeloid malignancies. Leukemia 2006; 20(7): 1295–1297.10.1038/sj.leu.2404233CrossRef Google Scholar

Oyarzo, MP, Lin, P, Glassman, A, Bueso-Ramos, CE, Luthra, R, Medeiros, LJ. Acute myeloid leukemia with t(6;9)(p23;q34) is associated with dysplasia and a high frequency of flt3 gene mutations. Am J Clin Pathol 2004; 122(3): 348–358.10.1309/5DGB59KQA527PD47CrossRef Google Scholar

Visconte, V, Shetty, S, Przychodzen, B, Hirsch, C, Bodo, J, Maciejewski, JP, et al. Clinicopathologic and molecular characterization of myeloid neoplasms with isolated t(6;9)(p23;q34). Int J Lab Hematol 2017; 39(4): 409–417.10.1111/ijlh.12641CrossRef Google Scholar

References

Bertrums, EJM, Smith, JL, Harmon, L, Ries, RE, Wang, YJ, Alonzo, TA, et al. Comprehensive molecular and clinical characterization of NUP98 fusions in pediatric acute myeloid leukemia. Haematologica 2023; 108(8): 2044–2058.10.3324/haematol.2022.281653CrossRef Google Scholar PubMed

Gough, SM, Slape, CI, Aplan, PD. NUP98 gene fusions and hematopoietic malignancies: Common themes and new biologic insights. Blood 2011; 118(24): 6247–6257.10.1182/blood-2011-07-328880CrossRef Google Scholar PubMed

Hollink, IH, van den Heuvel-Eibrink, MM, Arentsen-Peters, ST, Pratcorona, M, Abbas, S, Kuipers, JE, et al. NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. Blood 2011; 118(13): 3645–3656.10.1182/blood-2011-04-346643CrossRef Google Scholar

Struski, S, Lagarde, S, Bories, P, Puiseux, C, Prade, N, Cuccuini, W, et al. NUP98 is rearranged in 3.8% of pediatric AML forming a clinical and molecular homogenous group with a poor prognosis. Leukemia 2017; 31(3): 565–572.10.1038/leu.2016.267CrossRef Google Scholar

de Rooij, JD, Branstetter, C, Ma, J, Li, Y, Walsh, MP, Cheng, J, et al. Pediatric non-Down syndrome acute megakaryoblastic leukemia is characterized by distinct genomic subsets with varying outcomes. Nat Genet 2017; 49(3): 451–456.10.1038/ng.3772CrossRef Google Scholar PubMed

Jaju, RJ, Fidler, C, Haas, OA, Strickson, AJ, Watkins, F, Clark, K, et al. A novel gene, NSD1, is fused to NUP98 in the t(5;11)(q35;p15.5) in de novo childhood acute myeloid leukemia. Blood 2001; 98(4): 1264–1267.10.1182/blood.V98.4.1264CrossRef Google Scholar

Tian, J, Zhu, Y, Li, J, Yang, G, Weng, X, Huang, T, et al. The landscape of NUP98 rearrangements clinical characteristics and treatment response from 1491 acute leukemia patients. Blood Cancer J 2024; 14(1): 81.10.1038/s41408-024-01066-yCrossRef Google Scholar PubMed

Michmerhuizen, NL, Klco, JM, Mullighan, CC. Mechanistic insights and potential therapeutic approaches for NUP98-rearranged hematologic malignancies. Blood 2020; 136(20): 2275–2289.10.1182/blood.2020007093CrossRef Google Scholar PubMed

Noort, S, Wander, P, Alonzo, TA, Smith, J, Ries, RE, Gerbing, RB, et al. The clinical and biological characteristics of NUP98-KDM5A in pediatric acute myeloid leukemia. Haematologica 2021; 106(2): 630–634.10.3324/haematol.2019.236745CrossRef Google Scholar PubMed

de Rooij, JD, Hollink, IH, Arentsen-Peters, ST, van Galen, JF, Berna, Beverloo H, Baruchel, A, et al. NUP98/JARID1A is a novel recurrent abnormality in pediatric acute megakaryoblastic leukemia with a distinct HOX gene expression pattern. Leukemia 2013; 27(12): 2280–2288.10.1038/leu.2013.87CrossRef Google Scholar PubMed

Chisholm, KM, Heerema-McKenney, AE, Choi, JK, Smith, J, Ries, RE, Hirsch, BA, et al. Acute erythroid leukemia is enriched in NUP98 fusions: A report from the Children’s Oncology Group. Blood Adv 2020; 4(23): 6000–6008.10.1182/bloodadvances.2020002712CrossRef Google Scholar PubMed

References

Weinberg, OK, Porwit, A, Orazi, A, Hasserjian, RP, Foucar, K, Duncavage, EJ, et al. The International Consensus Classification of acute myeloid leukemia. Virchows Arch 2023; 482(1): 27–37.10.1007/s00428-022-03430-4CrossRef Google Scholar PubMed

Arber, DA, Orazi, A, Hasserjian, RP, Borowitz, MJ, Calvo, KR, Kvasnicka, HM, et al. International Consensus Classification of myeloid neoplasms and acute leukemias: Integrating morphologic, clinical, and genomic data. Blood 2022; 140(11): 1200–1228.10.1182/blood.2022015850CrossRef Google Scholar PubMed

Stengel, A, Haferlach, T, Baer, C, Hutter, S, Meggendorfer, M, Kern, W, et al. Specific subtype distribution with impact on prognosis of TP53 single-hit and double-hit events in AML and MDS. Blood Adv 2023; 7(13): 2952–2956.10.1182/bloodadvances.2022009100CrossRef Google Scholar PubMed

Tashakori, M, Kadia, T, Loghavi, S, Daver, N, Kanagal-Shamanna, R, Pierce, S, et al. TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia. Blood 2022; 140(1): 58–72.10.1182/blood.2021013983CrossRef Google Scholar PubMed

Fang, H, Wang, SA, Khoury, JD, El, Hussein S, Kim, DH, Tashakori, M, et al. Pure erythroid leukemia is characterized by biallelic TP53 inactivation and abnormal p53 expression patterns in de novo and secondary cases. Haematologica 2022; 107(9): 2232–2237.10.3324/haematol.2021.280487CrossRef Google Scholar PubMed

References

Westers, TM, Cremers, EM, Oelschlaegel, U Johansson, U, Bettelheim, P, Matarraz, S, et al. Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes: A report from the IMDSFlow working group. Haematologica 2017; 102(2): 308–319.10.3324/haematol.2016.147835CrossRef Google Scholar PubMed

Fang, H, Wang, SA, You, MJ, Hu, S, Miranda, RN, Tang, Z, et al. Flow cytometry immunophenotypic features of pure erythroid leukemia and the distinction from reactive erythroid precursors. Cytometry B Clin Cytom 2022; 102(6): 440–447.10.1002/cyto.b.22095CrossRef Google Scholar PubMed

Chen, K, Liu, J, Heck, S, Chasis, JA, An, X, Mohandas, N. Resolving the distinct stages in erythroid differentiation based on dynamic changes in membrane protein expression during erythropoiesis. Proc Natl Acad Sci USA 2009; 106(41): 17413–17418.10.1073/pnas.0909296106CrossRef Google Scholar PubMed

Liu, W, Hasserjian, RP, Hu, Y, Zhang, L, Miranda, RN, Medeiros, LJ, et al. Pure erythroid leukemia: A reassessment of the entity using the 2008 World Health Organization classification. Mod Pathol 2011; 24(3): 375–383.10.1038/modpathol.2010.194CrossRef Google Scholar PubMed

Dong, HY, Wilkes, S, Yang, H. CD71 is selectively and ubiquitously expressed at high levels in erythroid precursors of all maturation stages: A comparative immunochemical study with glycophorin A and hemoglobin A. Am J Surg Pathol 2011; 35(5): 723–732.10.1097/PAS.0b013e31821247a8CrossRef Google Scholar PubMed

Vaisman, B, Meyron-Holtz, EG, Fibach, E, Krichevsky, AM, Konijn, AM. Ferritin expression in maturing normal human erythroid precursors. Br J Haematol 2000; 110(2): 394–401.10.1046/j.1365-2141.2000.02167.xCrossRef Google Scholar PubMed

Wang, W, Grier, DD, Woo, J Ward, M, Sui, G, Torti, SV, et al. Ferritin H is a novel marker of early erythroid precursors and macrophages. Histopathology 2013; 62(6): 931–940.10.1111/his.12101CrossRef Google Scholar PubMed

Fang, H, Wang, SA, Khoury, JD, El, Hussein S, Kim, DH, Tashakori, M, et al. Pure erythroid leukemia is characterized by biallelic TP53 inactivation and abnormal p53 expression patterns in de novo and secondary cases. Haematologica 2022; 107(9): 2232–2237.10.3324/haematol.2021.280487CrossRef Google Scholar PubMed

Wang, SA, Hasserjian, RP. Acute erythroleukemias, acute megakaryoblastic leukemias, and reactive mimics: A guide to a number of perplexing entities. Am J Clin Pathol 2015; 144(1): 44–60.10.1309/AJCPRKYAT6EZQHC7CrossRef Google Scholar PubMed

References

Tomer, A. Human marrow megakaryocyte differentiation: Multiparameter correlative analysis identifies von Willebrand factor as a sensitive and distinctive marker for early (2 N and 4 N) megakaryocytes. Blood 2004; 104(9): 2722–2727.10.1182/blood-2004-02-0769CrossRef Google Scholar

Li, J, Kalev-Zylinska, ML. Advances in molecular characterization of pediatric acute megakaryoblastic leukemia not associated with Down syndrome: impact on therapy development. Front Cell Dev Biol 2023; 11: 1170622.10.3389/fcell.2023.1170622CrossRef Google Scholar

Taylor, J, Donoghue, MT, Ho, C, Petrova-Drus, K, Al-Ahmadie, HA, Funt, SA, et al. Germ cell tumors and associated hematologic malignancies evolve from a common shared precursor. J Clin Invest 2020; 130(12): 6668–6676.10.1172/JCI139682CrossRef Google Scholar PubMed

Brouwer, N, Matarraz, S, Nierkens, S, Hofmans, M, Novakova, M, da Costa, ES, et al. Immunophenotypic analysis of acute megakaryoblastic leukemia: A EuroFlow study. Cancers (Basel) 2022; 14(6): 1583.10.3390/cancers14061583CrossRef Google Scholar PubMed

Karandikar, NJ, Aquino, DB, McKenna, RW, Kroft, SH. Transient myeloproliferative disorder and acute myeloid leukemia in Down syndrome: An immunophenotypic analysis. Am J Clin Pathol 2001; 116(2): 204–210.10.1309/XREF-C9T2-6U0A-4EDTCrossRef Google Scholar PubMed

Langebrake, C, Creutzig, U, Reinhardt, D. Immunophenotype of Down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts. Klin Padiatr 2005; 217(3): 126–134.10.1055/s-2005-836510CrossRef Google Scholar PubMed

Zangrando, A, Cavagnero, F, Scarparo, P, Varotto, E, Francescato, S, Tregnago, C, et al. CD56, HLA-DR, and CD45 recognize a subtype of childhood AML harboring CBFA2T3–GLIS2 fusion transcript. Cytometry A 2021; 99(8): 844–850.10.1002/cyto.a.24339CrossRef Google Scholar PubMed

Eidenschink Brodersen, L, Alonzo, TA, Menssen, AJ, Gerbing, RB, Pardo, L, Voigt, AP, et al. A recurrent immunophenotype at diagnosis independently identifies high-risk pediatric acute myeloid leukemia: A report from Children’s Oncology Group. Leukemia 2016; 30(10): 2077–2080.10.1038/leu.2016.119CrossRef Google Scholar PubMed

Panda, D, Chatterjee, G, Sardana, R, et al. Utility of CD36 as a novel addition to the immunophenotypic signature of RAM-phenotype acute myeloid leukemia and study of its clinicopathological characteristics. Cytometry B Clin Cytom 2021; 100(2): 206–217.10.1002/cyto.b.21943CrossRef Google Scholar

Khanlari, M, Wang, L, Bolen, CY, Khanka, T, Ghogale, S, Deshpande, N, et al. CBFA2T3::GLIS2-positive acute leukemia with RAM and mixed T/megakaryocytic phenotype. EJHaem 2023; 4(3): 765–769.10.1002/jha2.741CrossRef Google Scholar PubMed

References

Zeijlemaker, W, Gratama, JW, Schuurhuis, GJ. Tumor heterogeneity makes AML a “moving target” for detection of residual disease. Cytometry B Clin Cytom 2014; 86(1): 3–14.10.1002/cytob.21134CrossRef Google Scholar PubMed

Wood, BL. Acute myeloid leukemia minimal residual disease detection: The difference from normal approach. Curr Protoc Cytom 2020; 93(1): e73.10.1002/cpcy.73CrossRef Google Scholar PubMed

Sidney, LE, Branch, MJ, Dunphy, SE, Dua, HS, Hopkinson, A. Concise review: Evidence for CD34 as a common marker for diverse progenitors. Stem Cells 2014; 32(6): 1380–1389.10.1002/stem.1661CrossRef Google Scholar PubMed

Chen, Z, Ok, CY, Wang, W, Goswami, M, Tang, G, Routbort, M, et al. Low-grade myelodysplastic syndromes with preserved CD34+ B-cell precursors (CD34+ hematogones). Cytometry B Clin Cytom 2020; 98(1): 36–42.10.1002/cyto.b.21830CrossRef Google Scholar PubMed

Payne, KJ, Crooks, GM. Human hematopoietic lineage commitment. Immunol Rev 2002; 187: 48–64.10.1034/j.1600-065X.2002.18705.xCrossRef Google Scholar PubMed

van Lochem, EG, van der Velden, VH, Wind, HK, te Marvelde, JG, Westerdaal, NA, van Dongen, JJ. Immunophenotypic differentiation patterns of normal hematopoiesis in human bone marrow: Reference patterns for age-related changes and disease-induced shifts. Cytometry B Clin Cytom 2004; 60(1): 1–13.10.1002/cyto.b.20008CrossRef Google Scholar

Pei, S, Shelton, IT, Gillen, AE, Stevens, BM, Gasparetto, M, Wang, Y, et al. A novel type of monocytic leukemia stem cell revealed by the clinical use of venetoclax-based therapy. Cancer Discov 2023; 13(9): 2032–2049.10.1158/2159-8290.CD-22-1297CrossRef Google Scholar PubMed

Terwijn, M, van Putten, WL, Kelder, A, van der Velden, VH, Brooimans, RA, Pabst, T, et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: Data from the HOVON/SAKK AML 42 A study. J Clin Oncol 2013; 31(31): 3889–3897.10.1200/JCO.2012.45.9628CrossRef Google Scholar

Walter, RB, Buckley, SA, Pagel, JM, Wood, BL, Storer, BE, Sandmaier, BM, et al. Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood 2013; 122(10): 1813–1821.10.1182/blood-2013-06-506725CrossRef Google Scholar PubMed

Ganzel, C, Sun, Z, Baslan, T, Zhang, Y, Gonen, M, Abdel-Wahab, OI, et al. Measurable residual disease by flow cytometry in acute myeloid leukemia is prognostic, independent of genomic profiling. Leuk Res 2022; 123: 106971.10.1016/j.leukres.2022.106971CrossRef Google Scholar PubMed

Wang, SA, Jorgensen, JL, Hu, S, Jia, F, Li, S, Loghavi, S, et al. Validation of a 12-color flow cytometry assay for acute myeloid leukemia minimal/measurable residual disease detection. Cytometry B Clin Cytom 2023; 104(5): 356–366.10.1002/cyto.b.22140CrossRef Google Scholar PubMed

Loghavi, S, DiNardo, CD, Furudate, K, Takahashi, K, Tanaka, T, Short, NJ, et al. Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemia. Br J Haematol 2021; 192(6): 1054–1063.10.1111/bjh.17347CrossRef Google Scholar PubMed

Laszlo, GS, Beddoe, ME, Godwin, CD, Bates, OM, Gudgeon, CJ, Harrington, KH, et al. Relationship between CD33 expression, splicing polymorphism, and in vitro cytotoxicity of gemtuzumab ozogamicin and the CD33/CD3 BiTE(R) AMG 330. Haematologica 2019; 104(2): e59–e62.10.3324/haematol.2018.202069CrossRef Google Scholar

Accessibility standard: Inaccessible, or known limited accessibility

Why this information is here

This section outlines the accessibility features of this content - including support for screen readers, full keyboard navigation and high-contrast display options. This may not be relevant for you.

Accessibility Information

The HTML of this chapter is known to have missing or limited accessibility features. We may be reviewing its accessibility for future improvement, but final compliance is not yet assured and may be subject to legal exceptions. If you have any questions, please contact accessibility@cambridge.org.

Content Navigation

Table of contents navigation
Allows you to navigate directly to chapters, sections, or non‐text items through a linked table of contents, reducing the need for extensive scrolling.

Index navigation
Provides an interactive index, letting you go straight to where a term or subject appears in the text without manual searching.

Reading Order & Textual Equivalents

Single logical reading order
You will encounter all content (including footnotes, captions, etc.) in a clear, sequential flow, making it easier to follow with assistive tools like screen readers.

Short alternative textual descriptions
You get concise descriptions (for images, charts, or media clips), ensuring you do not miss crucial information when visual or audio elements are not accessible.

Visual Accessibility

Use of colour is not sole means of conveying information
You will still understand key ideas or prompts without relying solely on colour, which is especially helpful if you have colour vision deficiencies.

Structural and Technical Features

ARIA roles provided
You gain clarity from ARIA (Accessible Rich Internet Applications) roles and attributes, as they help assistive technologies interpret how each part of the content functions.

Book contents

Section 4 - Acute Myeloid Leukemia

Summary

Information

Access options

Book purchase

Temporarily unavailable

References

References

References

References

References

References

References

References

References

References

References

References

References

References

Accessibility standard: Inaccessible, or known limited accessibility

Why this information is here

Accessibility Information

Content Navigation

Reading Order & Textual Equivalents

Visual Accessibility

Structural and Technical Features

Save book to Kindle

Save book to Dropbox

Save book to Google Drive